8 July 2016 - Rare Cancers Australia has lodged a submission for the reimbursement of MSD's Zolinza (vorinistat) for cutaneous T-cell lymphoma and Celgene's Istodax (romidepsin) for peripheral T-cell lymphoma.

Rare Cancers Australia (RCA) said it acknowledges a submission of this kind is unusual coming from a patient-focused charity.

"However, our decision to make this application was driven by a strong desire to both help those patients in need of these specific medicines and also to explore new and innovative ways that can bring PBS funded treatments to rare cancer patients in Australia," said RCA in a statement.

View Rare Cancers Australia statement